Background {#Sec1}
==========

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third cause of tumor-related death \[[@CR1]\]. Liver transplantation (LT) is an ideal option for well-selected HCC patients because this treatment completely removes not only the tumor but also the underlying cirrhotic liver disease \[[@CR2]\]. In 1996, the Milan criteria was introduced to optimize the clinical outcome of HCC patients after LT, but it has been proven to be too strict; a large proportion of patients with HCC beyond Milan criteria also have a substantial curative chance after LT. Thereafter, several expanded criteria were introduced in clinical practice \[[@CR3]-[@CR6]\]. The University of California San Francisco (UCSF) criteria and Hangzhou criteria were presented by Yao *et al.* in 2001 \[[@CR5]\] and by Zheng *et al.* in 2008 \[[@CR6]\], respectively.

Most of current selection criteria are based on tumor number, tumor size, and macro-vascular invasion which are evaluated by pre-transplant radiological imaging. However, the accuracy of radiological imaging is unsatisfactory, even unacceptable \[[@CR7]\]. On the other hand, the tumor biological behavior such as histological differentiation and micro-vascular invasion cannot be evaluated by radiological imaging, and these two factors are strongly associated with an increased risk of tumor recurrence after LT \[[@CR8]-[@CR10]\]. This situation prompts us to identify other predictors of HCC recurrence after LT.

Recently, systemic inflammation is proven to be related to poor prognosis and increased tumor progression. The tumor can upregulate the inflammatory process, and the inflammatory cells can release cytokines and mediators to promote angiogenesis, tumor proliferation, and metastasis \[[@CR11],[@CR12]\]. The platelet to lymphocyte ratio (PLR) has been used as a marker to evaluate the systemic inflammatory responses, and PLR is shown to be a prognostic factor in various tumors \[[@CR13]-[@CR15]\]. For HCC, conflicting data exist regarding the ability of PLR of predicting prognosis of HCC patients. Lai *et al.* demonstrate that PLR is a good predictor for the risk of post-LT recurrence \[[@CR16]\], but other studies fail to find correlation between PLR and clinical outcome of HCC patients \[[@CR17],[@CR18]\]. To date, the current opinion on the prognostic role of PLR in LT for HCC is still controversial. We therefore conducted this study to investigate the predictive value of PLR for post-transplant tumor recurrence.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

A total of 343 patients who received LT for HCC were enrolled in this retrospective study, and all the HCC developed in the background of liver cirrhosis which was confirmed by pathology of explant liver. The exclude criteria were (1) recipient age less than 18 years, (2) patients who died during the first month after LT, (3) recipients without adequate blood records and clinical data, and (4) patients with pre-transplant sepsis, hypersplenism, or massive gastrointestinal tract bleeding. All the LT were performed in the first affiliated hospital, School of Medicine, Zhejiang University, between January 2003 and December 2013.

Ethical approval was obtained from the Committee of Ethics in Biomedical Research of Zhejiang University and conformed to the ethical guidelines of the Declaration of Helsinki. Written informed consents were obtained from all participants.

Study design and data collection {#Sec4}
--------------------------------

The blood cell testing is performed every week or necessary before LT; the PLR was calculated as the ratio of platelet count to lymphocyte count according to the blood cell testing performed within 1 month before LT; if more than one set of measurement were available for a given patient, only the minimal PLR value was used. The HCC patients were divided into high PLR and low PLR groups according to the pre-transplant PLR values.

The definite diagnosis of HCC and the tumor-related characteristics including tumor number, tumor size, macro-vascular invasion, micro-vascular invasion, and tumor cell differentiation grading were judged based on pathological findings. The judgment of histological fulfillment of Milan criteria \[[@CR2]\], UCSF criteria \[[@CR5]\], or Hangzhou criteria \[[@CR6]\] for a given patients was based on pathological examination of explant livers.

The recipients' clinical variables including age, gender, model of end-stage liver disease (MELD) score, hepatitis B virus (HBV) infection status, and transplantation type (living donor liver transplantation \[LDLT\] or deceased donor liver transplantation \[DDLT\]) were collected and evaluated. The pre-transplant treatments of HCC were also recorded: surgical resection and interventional therapies including transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and percutaneous ethanol injection (PEI).

Follow-up {#Sec5}
---------

All transplanted recipients were followed up; the mean follow-up period was 33.7 months, ranged from 9.5 to 132.0 months. Screening for tumor recurrence was performed by α fetoprotein (AFP) measurement and ultrasonography every month during the first 6 months and performed every 2 months during the second 6 months. In the following years, the patients received examinations every 3 to 6 months or when necessary. Plain/enhanced thoracoabdominal computed tomography was performed every 6 months or when necessary. Bone scan or positron emission tomography was carried out in case of suspected HCC recurrence.

Statistical analysis {#Sec6}
--------------------

Data were summarized using mean with standard deviation (SD) for continuous variables and percentage for discrete variables. Student's *t* tests and Mann--Whitney *U* test were used for comparison of continuous with normal distribution and nonparametric distribution, respectively. Chi-square test was used for categorical variables. Survival analysis was performed using the Kaplan-Meier methods and compared using the log-rank test. Receiver operating characteristic (ROC) analysis was used to determine the PLR cut-off value with most significance in predicting tumor recurrence after LT; the optimal PLR cut-off value was considered when highest Youden index (sensitivity + specificity-1) was presented. Data were analyzed using SPSS 16.0 (SPSS Inc. Chicago, CA, USA). The *P* value \<0.05 was considered statistically significant.

Results {#Sec7}
=======

Clinical characteristics of 343 patients received LT for HCC {#Sec8}
------------------------------------------------------------

A total of 343 HCC patients including 308 (89.8%) males and 35 (10.2%) females were enrolled in this study; their mean age was 49.4 (from 19.0 to 71.0) years; the calculated MELD score before transplantation was 13.0 ± 6.0, 320 (93.3%) were HBV infected, 41 (12.0%) patients received LDLT, and 302 (88.0%) received DDLT. The mean follow-up period was 33.7 months, ranged from 9.5 to 132.0 months.

Of these patients, 144 (42.0%) patients fulfilled the Milan criteria; 166 (48.4%) and 193 (56.3%) patients were within the UCSF and Hangzhou criteria, respectively. Before LT, 52 (15.2%) patients received surgical tumor resections and 170 (49.6%) received interventional therapies.

Tumor-free survival of patients according to different PLR cut-off values {#Sec9}
-------------------------------------------------------------------------

The PLR cut-off values varied among different studies ranging from 100 to 300; some studies used PLR 160 or less, while others used more than 160 \[[@CR19]\]. As the first step, we used the ROC curve to determine the PLR cut-off value with the most significance in predicting HCC recurrence after LT. The area under ROC curve was 0.627, and the Youden index was highest when the PLR was 125; the sensitivity and specificity were 61.6% and 62.7%, respectively. Therefore, we considered PLR = 125 as the optimal cut-off (Figure [1](#Fig1){ref-type="fig"}). The 1-, 3-, and 5-year tumor-free survival rates were 66.8%, 54.6%, and 53.1% in PLR \<125 patients, respectively, significantly higher than 39.9%, 29.8%, and 29.8% in PLR ≥125 patients, respectively (Figure [2](#Fig2){ref-type="fig"}A). We further compared the overall patient survival rates between PLR ≥125 and \<125 patients; of patients with PLR \<125, the 1-, 3-, and 5-year overall patient survival rates were 81.0%, 63.6%, and 56.7%, respectively, significantly better than 67.3%, 45.0%, and 40.5% of patients in PLR ≥125 group, respectively (*P* = 0.012, Figure [2](#Fig2){ref-type="fig"}B).Figure 1**ROC curve for the PLR values to predict HCC recurrence after LT.** The area under ROC curve was 0.627. The PLR value 125 was considered as the optimal cut-off value because of its highest Youden index; the sensitivity and specificity were 61.6% and 62.7%, respectively.Figure 2**Comparison of tumor-free survival and overall patient survival between PLR ≥125 and \<125 patients.** The patients were divided into two groups according to the pre-transplant PLR cut-off value of 125. Recipients with PLR \<125 presented significantly higher tumor-free survival rates (*P* = 0.000, **(A)**) and overall patient survival rates (*P* = 0.012, **(B)**) than that with PLR ≥125.

In addition, because various PLR cut-off values were used in previous studies, we also compared the tumor-free survival rates according to different values. We found that significant differences were presented when PLR cut-off values of 100, 125, and 150 were used (Table [1](#Tab1){ref-type="table"}). Of these, the cut-off value of 125 was the most significant (*P* = 0.000). In the next analysis, we used the PLR 125 as the cut-off value.Table 1**Tumor-free survival rates of patients according to different PLR cut-off valuesCut-off values*n*Tumor-free survival rates (%)** ^**a**^***P*** **value1 year3 years5 years**PLR ≥5025865.8 *vs.* 62.252.1 *vs.* 50.249.8 *vs.* 49.40.710PLR ≥10010367.8 *vs.* 49.555.9 *vs.* 38.054.3 *vs.* 38.00.003PLR ≥1255566.8 *vs.* 39.954.6 *vs.* 29.853.1 *vs.* 29.80.000PLR ≥1503365.6 *vs.* 39.353.4 *vs.* 24.752.1 *vs.* 24.70.001PLR ≥200863.5 *vs.* 42.950.8 *vs.* 42.949.6 *vs.* 42.90.380^a^Tumor-free survival rates in the high *vs.* low PLR group.

Comparison of recipients' clinical characteristics between PLR ≥125 and PLR \<125 groups {#Sec10}
----------------------------------------------------------------------------------------

Patients with PLR \<125 showed better prognosis than that with PLR ≥125; the clinical backgrounds of recipients in two groups were then compared. As shown in Table [2](#Tab2){ref-type="table"}, between PLR \<125 and ≥125 groups, the clinical variables including age, gender, MELD score, HBV infection status, and transplantation type were comparable, and the pre-transplant HCC treatments including surgical resection and interventional therapies were also similar. This result indicated that the clinical characteristics of recipients in two groups were comparable.Table 2**Comparison of clinical characteristics between PLR ≥125 and PLR \<125 groupsVariablesPLR*P*** **value\<125 (** ***n***  **= 288)≥125 (** ***n***  **= 55)**Age (years)49.6 ± 8.648.5 ± 11.10.480Gender (male)260 (90.3%)48 (87.3%)0.500MELD score13.0 ± 6.012.7 ± 6.50.755Types of LT  LDLT35 (12.2%)6 (10.9%)0.794  DDLT253 (87.8%)49 (89.1%)HBV infection270 (93.8%)50 (90.9%)0.390Pre-LT treatment  Surgical resection43 (17.1%)9 (9.8%)0.786  Interventional therapy139 (48.3%)31 (56.4%)0.271

Influences of tumor-related characteristics on tumor-free survival {#Sec11}
------------------------------------------------------------------

We next examined that whether the different tumor recurrence was caused by disparity of tumor-related characteristics (tumor number, largest and total tumor size, macro- and micro-vascular invasion, tumor differentiation, pre-transplant AFP level and fulfill of Milan, UCSF, or Hangzhou criteria) between two groups or not. We analyzed the influences of tumor-related characteristics on tumor-free survival rates. As shown in Table [3](#Tab3){ref-type="table"}, all of the tumor-related characteristics examined in this study were proven to be predictive for tumor-free survival after LT.Table 3**Influence of tumor-related characteristics on tumor-free survival ratesTumor-related characteristics*n*Tumor-free survival rates (%)*P*** **value1 year3 years5 years**Tumor number \>39130.320.016.60.000 ≤325274.061.460.7Maximal tumor size (cm) ≤523371.962.161.20.000 5 to 85456.442.136.9 \>85627.311.811.8Total tumor size (cm) ≤515481.873.073.00.000 5 to 85471.953.353.3 \>813536.023.019.9Macro-vascular invasion Yes10138.918.018.00.000 No24271.963.561.9Micro-vascular invasion Yes14244.426.124.90.000 No20174.868.066.9Differentiation Poor14856.843.542.10.003 Moderate17163.852.451.3 Well2495.881.281.2AFP level (ng/ml) ≥20017846.933.531.40.000 \<20016580.470.670.6Milan criteria Yes14485.776.776.70.000 No19945.030.528.1UCSF criteria Yes16684.375.675.60.000 No17741.526.223.6Hangzhou criteria Yes19383.374.274.20.000 No15035.120.017.3

Relationship between PLR value and tumor-related characteristics {#Sec12}
----------------------------------------------------------------

We then evaluated the distribution of tumor-related characteristics in PLR ≥125 and \<125 groups. We found that patients with PLR ≥125 displayed high proportion of multiple tumors, large tumor size, and micro- and macro-vascular invasion, but there was no difference between two groups in terms of tumor differentiation and AFP levels. For histological fulfillment of selection criteria, 46.9%, 54.2%, and 61.5% patients with PLR \<125 were within Milan, UCSF, and Hangzhou criteria, respectively, significantly higher than 16.4%, 18.2%, and 29.1% in PLR ≥125 group, respectively (Table [4](#Tab4){ref-type="table"}). This result indicated that patients with PLR ≥125 tended to be associated with multiple tumors, large tumor size, and micro- and macro-vascular invasion, and this disparity maybe the explanation of the poor prognosis of patients with PLR ≥125.Table 4**Relationship between PLR value and tumor-related characteristicsVariablesPLR*P*** **value\<125 (** ***n*** **= 288)≥125 (** ***n*** **= 55)**Tumor number \>369 (24.0%)22 (40.0%)0.014Largest tumor size (cm) ≤5214 (74.3%)19 (34.5%)0.000 5 to 843 (14.9%)11 (20.0%) \>831 (10.8%)25 (45.5%)Total tumor size (cm) ≤5144 (50.0%)10 (18.2%)0.000 5 to 846 (16.0%)8 (14.5%) \>898 (34.0%)37 (67.3%)Macro-vascular invasion78 (27.1%)23 (41.8%)0.028Micro-vascular invasion109 (37.8%)33 (60.0%)0.002Tumor differentiation Poor124 (43.1%)24 (43.6%)0.246 Moderate141 (49.0%)30 (54.5%) Well23 (8.0%)1 (1.8%)AFP ≥200 ng/ml136 (47.2%)32 (58.2%)0.147Within Milan criteria135 (46.9%)9 (16.4%)0.000Within UCSF criteria156 (54.2%)10 (18.2%)0.000Within Hangzhou criteria177 (61.5%)16 (29.1%)0.000

Comparison of HCC recurrence according to platelet and lymphocyte counts {#Sec13}
------------------------------------------------------------------------

About the molecular mechanisms of relationship between PLR and tumor recurrence, it is hypothesized that patients with elevated PLR have a high percentage of platelet which can secrete cytokines to stimulate angiogenesis and tumor progression and low percentage of lymphocytes which play a vital role in antitumor immunological response. To check this explanation, we compared HCC recurrence according to the platelet and lymphocyte counts. The patients were divided according to the mean platelet count, those with high (≥100.3\*10^9^/L, *n* = 182) and low (\<100.3\*10^9^/L, *n* = 161) platelet groups. The 1-, 3-, and 5-year tumor-free survival rates were 68.8%, 55.7%, and 54.6% in the low platelet group, respectively, comparable with 56.7%, 46.1%, and 44.5% in the high platelet group, respectively (*P* = 0.079, Table [5](#Tab5){ref-type="table"}). For the lymphocyte count, patients were also divided according to the mean lymphocyte count. We found that the 1-, 3-, and 5-year tumor-free survival rates were 56.4%, 49.1%, and 47.4%, respectively, in the high lymphocyte group (≥1.1\*10^9^/L, *n* = 130), similar with 69.4%, 54.2%, and 53.2%, respectively, in the low lymphocyte group (\<1.1\*10^9^/L, *n* = 213) (*P* = 0.168, Table [5](#Tab5){ref-type="table"}).Table 5**Comparison of tumor-free survival according to platelet and lymphocyte counts independentlyGroups*n*Tumor-free survival rates (%)*P*** **value1 year3 years5 years**Platelet count  High (≥100.3\*10^9^/L)18256.746.144.50.079  Low (\<100.3\*10^9^/L)16168.855.754.6Lymphocyte count  High (≥1.1\*10^9^/L)13056.449.147.40.168  Low (\<1.1\*10^9^/L)21369.454.253.2

Discussion {#Sec14}
==========

Since the induction of Milan criteria by Mazzaferro *et al.* in 1996, excellent clinical outcome after LT was achieved for HCC patients within Milan criteria \[[@CR2],[@CR20]\]. In the following decades, the selection criteria were expanded properly without sacrificing clinical outcomes \[[@CR5],[@CR6]\]. But most of current selection criteria are based solely on pre-transplant radiological imaging, with no consideration of the tumor biological behavior. As a result, nearly 15% \~ 20% recurrence rates of HCC after LT are reported in patients who fulfill the Milan or UCSF criteria \[[@CR21],[@CR22]\].

On the other hand, pre-transplant radiological imaging is reported to be inaccurate \[[@CR7]\]. In most cases, pre-transplant radiological imaging always underestimates the real tumor status because of the limitation in finding small tumor lesions. Simultaneously, radiological examination cannot evaluate the tumor differentiation and micro-vascular invasion which are strongly associated with an increased risk of tumor recurrence after LT \[[@CR8]-[@CR10]\]. Despite being within Milan or UCSF criteria, patients with these characteristics will likely response poorly to LT.

In recently years, accumulative evidences have demonstrated that increased systemic inflammation is related to poor prognosis of various kinds of cancers including colorectal cancer, pancreatic cancer, and prostate cancer \[[@CR23]-[@CR25]\]. PLR is a simple marker of systemic inflammation and can be obtained easily from routine blood cell testing. In this study, we identified that PLR ≥125 showed most significant correlation with tumor recurrence. Furthermore, we compared the clinical background and tumor-related characteristics between PLR ≥125 and \<125 groups; we found that PLR ≥125 was associated with high proportion of multiple tumors, large tumor size, and micro- and macro-vascular invasion, and PLR ≥125 was prone to be beyond Milan, UCSF, and Hangzhou criteria. But we failed to find correlations of PLR with tumor histological differentiation and AFP levels. The association of PLR- and tumor-related characteristics was explored in previous studies. Kwon *et al.* showed that patients with higher PLR showed a higher likelihood of positive lymph node in colorectal cancer \[[@CR26]\]. In cervical cancer, increased PLR was related to bigger tumor size and lymph node metastasis \[[@CR27]\]. Azab *et al.* reported that increased PLR predicted a higher rate of lymph node involvement, higher rate of metastasis, and higher American Joint Committee on Cancer (AJCC) staging in breast cancer patients \[[@CR28]\]. To our knowledge, it is the first study to investigate the relationship between PLR- and HCC-related characteristics, and our finding indicated elevated PLR implying high possibility of advanced tumor stage and aggressive tumor phenotype.

The molecular mechanisms involved in the relationship between PLR and tumor recurrence still remains unclear; one explanation is that patients with elevated PLR have a high percentage of platelets and low percentage of lymphocytes. The platelets can secret vascular endothelial growth factor (VEGF) which can cause angiogenesis and tumor progression \[[@CR29]\]. The low percentage of lymphocytes indicated impaired host immunological response to malignancy \[[@CR30]\]. But our results did not support this explanation, we failed to find differences of tumor-free survival between high and low platelet count groups or between high and low lymphocyte count groups. Recent study indicated that tumor microenvironment maybe involved in the association of systematic inflammation with tumor recurrence \[[@CR31]\]; however, the detailed mechanisms are unclear and need further study.

Conclusions {#Sec15}
===========

Our study identified that elevated pre-transplant PLR was associated with advanced tumor stage and aggressive tumor phenotype, and pre-transplant PLR can be used as a prognostic factor for post-transplant tumor recurrence.
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